Discontinued — last reported Q3 '23
Charles Schwab Corporation Interest Paid decreased by 8.4% to $985.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 31.7%, from $1.44B to $985.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 73.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $106.00M | $151.00M | $121.00M | $153.00M | $133.00M | $436.00M | $633.00M | $923.00M | $1.21B | $1.72B | $1.77B | $1.96B | $1.61B | $1.65B | $1.44B | $1.19B | $1.30B | $1.08B | $985.00M |
| QoQ Change | — | +42.5% | -19.9% | +26.4% | -13.1% | +227.8% | +45.2% | +45.8% | +31.3% | +41.6% | +3.3% | +10.4% | -17.7% | +2.1% | -12.3% | -17.3% | +9.3% | -17.6% | -8.4% |
| YoY Change | — | — | — | — | +25.5% | +188.7% | +423.1% | +503.3% | +811.3% | +293.6% | +179.9% | +112.0% | +32.9% | -4.1% | -18.6% | -39.0% | -19.1% | -34.7% | -31.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.